Clinical Trial: Rapid Response to Second-generation ALK Inhibitor in Lung Adenocarcinoma with Lymphangitic Carcinomatosis and Severe Anemia: A Case Report (China)

Posted On: 2026-09-23

China, Sept. 23 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Rapid Response to Second-generation ALK Inhibitor in Lung Adenocarcinoma with Lymphangitic Carcinomatosis and Severe Anemia: A Case Report'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133153

Registration Time: 2026/09/22

Type: Observational study

Primary Sponsor: Jiangxi Cancer Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=311851

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Rapid Response to Second-generation ALK Inhibitor in Lung Adenocarcinoma with Lymphangitic Carcinomatosis and Severe Anemia: A Case Report (China)